BioSpace News Archive

Bristol Myers Squibb will take part in a fireside chat at the 41st Annual Goldman Sachs Global Healthcare Conference, which will be webcast on June 11, 2020.

Following meetings with both the U.S. FDA and EMA, Can-Fite is ready to submit its protocol and conduct one pivotal trial for registration in both markets

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company will participate in the BIO International Convention, which will be held in a new, virtual event format for 2020, known as BIO Digital, from June 8-12, 2020. Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will participate in a panel discussion titled Redefining BioPharma in a Female-Forward World and will separately provid

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at two upcoming investor conferences in June. Goldman Sachs 41 st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 2:10 p.m.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced the appointment of Gianluca Pirozzi, M.D., Ph.D. and Edward J. Sitar t

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S. Zoth, CPA to its Board of Directors and as Chair of the Audit Committee. A veteran of the biopharmaceutical industry, Ms. Zoth brings more than 35 years of financial and strategic experience to her role.

IQ4I Research & Consultancy published a new report on “Cancer Diagnostics Global Market – Forecast To 2026".

Seven Bridges, the industry-leading bioinformatics ecosystem provider, today announced the successful completion of independent examinations for SOC 2 Type 2, SOC 3 and HIPAA. The examinations were conducted by independent service auditor Schellman and Company, LLC. These additions to the Seven Bridges compliance portfolio complement the compa

Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide clinical development of its lead clinical-stage

June 4, 2020 12:00 UTC Aimmune Therapeutics to Present at the Goldman Sachs 41 st Annual Global Healthcare Conference